496 related articles for article (PubMed ID: 36211665)
1. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
Luo X; Zhou Z; Zeng X; Peng L; Liu Q
Front Public Health; 2022; 10():985834. PubMed ID: 36211665
[TBL] [Abstract][Full Text] [Related]
2. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
[TBL] [Abstract][Full Text] [Related]
3. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
Zhao M; Shao T; Shao H; Zhou C; Tang W
BMC Cancer; 2024 Feb; 24(1):186. PubMed ID: 38331773
[TBL] [Abstract][Full Text] [Related]
4. Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece.
Gourzoulidis G; Zisimopoulou O; Liavas A; Tzanetakos C
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):375-385. PubMed ID: 37997764
[TBL] [Abstract][Full Text] [Related]
5. Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer.
Li H; Lai L; Wu B
Clin Drug Investig; 2020 Feb; 40(2):183-189. PubMed ID: 31820329
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective.
Cranmer H; Kearns I; Young M; Humphries MJ; Trueman D
J Manag Care Spec Pharm; 2022 Sep; 28(9):970-979. PubMed ID: 36001099
[No Abstract] [Full Text] [Related]
7. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
Wang L; Sheng Z; Zhang J; Song J; Teng L; Liu L; Li Q; Wang B; Li B
J Chemother; 2022 Apr; 34(2):87-96. PubMed ID: 34139965
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
[TBL] [Abstract][Full Text] [Related]
9. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
Ma HC; Liu YH; Ding KL; Liu YF; Zhao WJ; Zhu YJ; Chang XS; Chen YD; Xiao ZZ; Yu YY; Zhou R; Zhang HB
BMC Cancer; 2021 Nov; 21(1):1278. PubMed ID: 34836510
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.
Carlson JJ; Canestaro W; Ravelo A; Wong W
J Med Econ; 2017 Jul; 20(7):671-677. PubMed ID: 28332433
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer.
Liu W; Huo G; Chen P
Front Public Health; 2024; 12():1213318. PubMed ID: 38435286
[TBL] [Abstract][Full Text] [Related]
13. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Cameron LB; Hitchen N; Chandran E; Morris T; Manser R; Solomon BJ; Jordan V
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013453. PubMed ID: 34994987
[TBL] [Abstract][Full Text] [Related]
15. A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer.
Zheng B; Jiang H; Yang W; Li Y; Liang B; Zhu J; Chen N; Chen M; Zhang M
Cancer Med; 2023 Aug; 12(15):15983-15997. PubMed ID: 37334877
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China.
Guan H; Sheng Y; Guo W; Han S; Shi L
Adv Ther; 2019 May; 36(5):1114-1125. PubMed ID: 30900201
[TBL] [Abstract][Full Text] [Related]
17. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).
Chayab L; Konstantelos N; Leighl NB; Tadrous M; Wong WWL
Pharmacoeconomics; 2023 Aug; 41(8):945-980. PubMed ID: 37268866
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer.
Reckamp K; Lin HM; Huang J; Proskorovsky I; Reichmann W; Krotneva S; Kerstein D; Huang H; Lee J
Curr Med Res Opin; 2019 Apr; 35(4):569-576. PubMed ID: 30286627
[TBL] [Abstract][Full Text] [Related]
20. ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis.
Jiang J; Zhao C; Zhang F; Liu Z; Zhou K; Ren X; Wan Y
BMJ Open; 2022 Sep; 12(9):e060782. PubMed ID: 36123063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
